Dysadherin Antibody (D-2): sc-166782
- Dysadherin Antibody (D-2) is a mouse monoclonal IgG1 κ, cited in 4 publications, provided at 200 µg/ml
- raised against amino acids 1-178 representing full length Dysadherin of human origin
- recommended for detection of Dysadherin isoform 1 and 2 of human origin by WB, IP, IF and ELISA
- m-IgG1 BP-HRP is the preferred secondary detection reagent for Dysadherin Antibody (D-2) for WB applications. This reagent is now offered in a bundle with Dysadherin Antibody (D-2) (see ordering information below).
QUICK LINKS
SEE ALSO...
Dysadherin Antibody (D-2) is a mouse monoclonal IgG1 antibody that detects Dysadherin in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Dysadherin, also known as FXYD domain-containing ion transport regulator 5, plays a critical role in cancer progression by down-regulating E-cadherin, the key protein responsible for maintaining cell-cell adhesion in epithelial tissues. This down-regulation occurs through a posttranscriptional mechanism, which ultimately reduces intercellular adhesion and facilitates the metastasis of cancer cells, making Dysadherin a significant marker in cancer research. Dysadherin is predominantly located in the cell membrane, particularly in tissues such as the spleen, lung, skeletal muscle, and testis, and is mapped to human chromosome 19q13. Dysadherin expression in these tissues underscores potential impact on cellular interactions and tumor biology, highlighting importance as a target for therapeutic interventions and diagnostic applications. Anti-Dysadherin antibody (D-2) is an essential tool for researchers investigating the mechanisms of cancer metastasis and the role of cell adhesion in tumor progression.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Dysadherin Antibody (D-2) References:
- Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression. | Izumi, T., et al. 2007. Am J Surg Pathol. 31: 85-94. PMID: 17197923
- Dysadherin: a new player in cancer progression. | Nam, JS., et al. 2007. Cancer Lett. 255: 161-9. PMID: 17442482
- Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. | Park, JR., et al. 2011. J Hepatol. 54: 122-31. PMID: 20952084
- Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer. | Georgolios, A., et al. 2012. Med Oncol. 29: 1463-7. PMID: 22105147
- Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation. | Lee, YK., et al. 2012. Cancer Sci. 103: 1280-9. PMID: 22494103
- Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes. | Jang, S., et al. 2017. Oncotarget. 8: 24457-24468. PMID: 28160550
- Dysadherin awakens mechanical forces and promotes colorectal cancer progression. | Park, SY., et al. 2022. Theranostics. 12: 4399-4414. PMID: 35673579
- Prognostic value of dysadherin in cancer: A systematic review and meta-analysis. | Niinivirta, A., et al. 2022. Front Oncol. 12: 945992. PMID: 36119538
- The dysadherin/FAK axis promotes individual cell migration in colon cancer. | Lee, CJ., et al. 2024. Int J Biol Sci. 20: 2356-2369. PMID: 38725858
- The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression. | Lee, CJ., et al. 2024. Nat Commun. 15: 10422. PMID: 39613801
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dysadherin Antibody (D-2) | sc-166782 | 200 µg/ml | $322.00 | |||
Dysadherin Antibody (D-2): m-IgG1 BP-HRP Bundle | sc-542669 | 200 µg Ab; 20 µg BP | $361.00 |